These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10220617)

  • 21. Ischemic burden, treatment allocation, and outcomes in stable coronary artery disease.
    Farzaneh-Far A; Borges-Neto S
    Circ Cardiovasc Imaging; 2011 Nov; 4(6):746-53. PubMed ID: 22086945
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The euros and sense of stents: do we get value for money?
    Annemans L
    J Cardiovasc Med (Hagerstown); 2011 Dec; 12(12):878-82. PubMed ID: 22025203
    [No Abstract]   [Full Text] [Related]  

  • 24. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).
    Kaiser C; Brunner-La Rocca HP; Buser PT; Bonetti PO; Osswald S; Linka A; Bernheim A; Zutter A; Zellweger M; Grize L; Pfisterer ME;
    Lancet; 2005 Sep 10-16; 366(9489):921-9. PubMed ID: 16154019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shifting the balance: direct stenting a novel approach to improve the cost effectiveness of intra-coronary stenting.
    Cotton JM; Kearney MT; Wainwright RJ
    Eur Heart J; 2000 Jan; 21(2):170. PubMed ID: 10637091
    [No Abstract]   [Full Text] [Related]  

  • 26. Funding of coronary angioplasty in public hospitals.
    Eccleston DS; Eisenberg MJ
    Aust N Z J Med; 1996 Jun; 26(3):430-1. PubMed ID: 8811228
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care.
    Shrive FM; Ghali WA; Johnson JA; Donaldson C; Manns BJ
    Med Care; 2007 Mar; 45(3):269-73. PubMed ID: 17304086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To stent or not to stent?: A sterile debate.
    Westaby S; Channon K; Banning A
    BMJ; 2007 Jul; 335(7611):111. PubMed ID: 17641307
    [No Abstract]   [Full Text] [Related]  

  • 29. Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.
    Weintraub WS
    Circulation; 2004 Aug; 110(5):472-4. PubMed ID: 15289386
    [No Abstract]   [Full Text] [Related]  

  • 30. Transradial interventions: quality of life and economic issues.
    Shiek M; Pandya U; Cooper CJ
    Indian Heart J; 2008; 60(1 Suppl A):A51-3. PubMed ID: 19359750
    [No Abstract]   [Full Text] [Related]  

  • 31. Coronary angioplasty: is cardiological practice in the U.S.A. really the gold standard for Europe?
    Cleland JG
    Eur Heart J; 1993 Oct; 14(10):1435-7. PubMed ID: 8262093
    [No Abstract]   [Full Text] [Related]  

  • 32. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of costs of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG) for patients with angina pectoris.
    Cheng TO
    Eur Heart J; 1991 Feb; 12(2):288. PubMed ID: 1904352
    [No Abstract]   [Full Text] [Related]  

  • 34. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators.
    Cohen DJ; Krumholz HM; Sukin CA; Ho KK; Siegrist RB; Cleman M; Heuser RR; Brinker JA; Moses JW; Savage MP
    Circulation; 1995 Nov; 92(9):2480-7. PubMed ID: 7586348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis.
    Brunner-La Rocca HP; Kaiser C; Bernheim A; Zellweger MJ; Jeger R; Buser PT; Osswald S; Pfisterer M;
    Lancet; 2007 Nov; 370(9598):1552-9. PubMed ID: 17980734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions.
    Fearon WF; Yeung AC; Lee DP; Yock PG; Heidenreich PA
    Am Heart J; 2003 May; 145(5):882-7. PubMed ID: 12766748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness of drug-eluting stents: implications for clinical practice and healthcare costs].
    Oliva G
    Rev Esp Cardiol; 2006 Sep; 59(9):865-8. PubMed ID: 17020698
    [No Abstract]   [Full Text] [Related]  

  • 38. The dollars and sense of drug-eluting stents.
    Brophy JM
    CMAJ; 2005 Feb; 172(3):361-2. PubMed ID: 15684119
    [No Abstract]   [Full Text] [Related]  

  • 39. Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery.
    Iakovou I; Dangas G; Mehran R; Lansky AJ; Stamou SC; Pfister AJ; Dullum MK; Leon MB; Corso PJ
    Am J Cardiol; 2002 Oct; 90(8):885-7. PubMed ID: 12372581
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-eluting coronary stents: faith and hope, but no charity.
    Knudtson ML
    CMAJ; 2007 Jan; 176(2):195-6. PubMed ID: 17179218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.